Empowering Health
Through Clinical Trials
Discovering hope, advancing medicine and strengthening patient communities
The Importance of Clinical Trials for Disease Research
Uncovering medical breakthroughs starts with clinical trials. Each presents an opportunity to offer early access to innovative treatments that may enhance the lives of patients. Tanabe Pharma America is driving discovery every day through smart science with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases.
TPA has several clinical trials that are currently recruiting:
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP (INSPIRE): NCT06144840
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP): NCT05005975
Clinical Trials
We developed our IITs Program in order to provide support for Investigator-Initiated clinical research or Health Economics Outcome Independent Research that illustrates the potential to foster knowledge and understanding of TPA’s product(s). This program is integral to driving scientific and clinical knowledge and improving quality of life and care for patients.
Explore our policies and procedures for evaluating and responding to requests for expanded access to our investigational drugs.
Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
TPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
TPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if TPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.